Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 1—January 2011

Endurance, Refuge, and Reemergence of Dengue Virus Type 2, Puerto Rico, 1986–2007

Article Metrics
citations of this article
EID Journal Metrics on Scopus
Kate L. McElroy1, Gilberto A. Santiago1, Niall J. Lennon, Bruce W. Birren, Matthew R. Henn1, and Jorge L. Muñoz-Jordán1Comments to Author 
Author affiliations: Author affiliations: Centers for Disease Control and Prevention, San Juan, Puerto Rico (K.L. McElroy, G.A. Santiago, J.L. Muñoz-Jordán); Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA (N.J. Lennon, B.W. Birren, M.R. Henn)

Cite This Article


To study the evolution of dengue virus (DENV) serotype 2 in Puerto Rico, we examined the genetic composition and diversity of 160 DENV-2 genomes obtained through 22 consecutive years of sampling. A clade replacement took place in 1994–1997 during a period of high incidence of autochthonous DENV-2 and frequent, short-lived reintroductions of foreign DENV-2. This unique clade replacement was complete just before DENV-3 emerged. By temporally and geographically defining DENV-2 lineages, we describe a refuge of this virus through 4 years of low genome diversity. Our analyses may explain the long-term endurance of DENV-2 despite great epidemiologic changes in disease incidence and serotype distribution.

Epidemic dengue fever (DF) and the emergence of dengue hemorrhagic fever (DHF) in the Americas are associated with increased endemicity and cocirculation of the 4 dengue virus (DENV) serotypes, 1–4 (1). These increases have been particularly evident in Puerto Rico, where transmission increased during the past 25 years (24). The first DHF epidemics in the Americas occurred in the 1980s and were caused by the Asian/American genotype of DENV-2, then new to the region, which rapidly replaced the American genotype (57). This replacement has been linked to a potential to cause higher viremia and severe illness (810). Introduction of DENV-3 in the mid 1990s and increased human population and travel further fostered larger and more frequent DF and DHF epidemics in the region (1113).

Although all 4 DENV serotypes circulate on the island, DENV-2 circulated continuously for 25 years. Previously, a partial sequence analysis from 74 DENV-2 isolates collected in Puerto Rico during 7 years throughout a 14-year period (1987–2001) showed a DENV-2 lineage evolving through a series of turnover events (14). A lineage replacement in 1994 appeared to be associated with a foreign virus but only 3 other reintroductions were found, all linked to the 1998 epidemic, the largest in Puerto Rico history (14). This was a turning point in the epidemiology of dengue, with DENV-2 (and DENV-1 and -4) rapidly declining during the expansion of DENV-3. However, transmission of DENV-2 persisted at low levels during 1999–2003 and increased thereafter. This serotype turnover offers new opportunities to study the evolution of DENV-2. Our analysis illustrates the genetic composition and population diversity of DENV-2 throughout 22 consecutive years of sampling in Puerto Rico and may explain the evolutionary resilience and long-term establishment of this virus.


Virus Isolates

We complied with the institutional review boards of the Centers for Disease Control and Prevention (CDC) (protocol 4797) and the Broad Institute of MIT and Harvard. DENV was obtained from human serum received through the passive surveillance system administered by CDC. Each sample was accompanied by a form that captured geographic and clinical information maintained for this study without patient identifiers. Primary or secondary status of infection was inferred by absence or presence of serum immunoglobulin G (15). Viruses were rescued into C6/36 cells (16). Selection of 3 isolates per year in the 5 municipalities with the highest reporting of DENV-2 cases resulted in 253 isolates, of which 140 were successfully sequenced and are representative of our virus repository with respect to patient age (27.7 vs. 22.6 years), sex (54.4% vs. 47.4% male), and history of infection (84.6% vs. 77% secondary infections). We also sequenced 20 regional isolates from neighboring countries.


We extracted RNA from tissue culture supernatant using the M48 or MDx BioRobot (QIAGEN, Valencia, CA, USA). cDNA was generated by using Sensiscript RT (QIAGEN) with random hexamers (Applied Biosciences, Foster City, CA, USA). Presence of cDNA was confirmed by PCR by using PfuUltraII (Stratagene, La Jolla, CA, USA) or iTaq (Bio-Rad, Hercules, CA, USA) DNA polymerase and specific oligonucleotides (CDC, Atlanta, GA, USA). Fourteen pooled overlapping 2,000 nt amplicons were generated by reverse transcription–PCR at CDC (San Juan, PR) and sequenced at the Broad Institute (Cambridge, MA, USA) by bidirectional Sanger by using an ABI 3730 after PCR with 96 M13-tailed serotype-specific primers. Resulting reads were trimmed of the primer sequences, filtered for high quality, and assembled by using algorithms developed by the Broad Institute. All coding sequences for the poliproteins (10,173 nt) and parts of the 5′ and 3′ noncoding regions were deposited in GenBank.

Sequence Analyses

Coding sequences for the unprocessed polyprotein (5′ and 3′ noncoding regions excluded) were aligned by ClustalW software ( in MEGA 4 ( Maximum likelihood analysis and bootstrapping tests were performed in PAUP* (16) under the best-fit substitution model estimated by MODELTEST v3.07 (14) (parameters available on request). The 1983 Jamaican isolate JM_83_M20558 (5) served as outgroup. Mean rates of nucleotide substitution and relative genetic diversity (Net, where t is the generation time) were estimated by using Bayesian Markov Chain Monte Carlo (MCMC) from BEAST v1.4.7 ( General time reversible substitution model with strict and relaxed molecular clocks and constant population size or Bayesian Skyline coalescent analysis was used. All MCMC chains were run for sufficient length ensuring stationary parameters, with statistical error reflected in values of the 95% highest probability density. Amino acid differences were mapped by using parsimony methods in MacClade v4.08 (17). We determined dN/dS ratios with the single likelihood ancestor counting method using HYPHY and accessed through the Datamonkey server (13). Associations between phylogeny and geographic data were investigated by using Bayesian Tip-association Significance testing ( with the posterior sample of trees calculated by BEAST. For the parsimony score, association index, and monophyletic clade size, we considered p<0.05 significant.


Figure 1

Thumbnail of Historic overview of dengue, Puerto Rico, 1986–2007. A) Number of suspected, clinically defined cases of dengue fever/dengue hemorrhagic fever by year reported to the Centers for Disease Control and Prevention’s Dengue Branch. B) Percentage of identifications of each serotype relative to the total of positive serotype identifications by using tissue culture isolation or reverse transcription–PCR per year. Numbers in parenthesis indicate numbers of dengue virus (DENV) serotype 2 iden

Figure 1. Historic overview of dengue, Puerto Rico, 1986–2007. A) Number of suspected, clinically defined cases of dengue fever/dengue hemorrhagic fever by year reported to the Centers for Disease Control and Prevention’s Dengue...

During 1986–2007, dengue cases in Puerto Rico ranged from 2,000 to ≈16,000 per year (Figure 1, panel A), with major epidemics (>8,000 cases) reported in 1986, 1992, 1994, 1998, and 2007 (24,18,19). Despite major fluctuations in serotype circulation, DENV-2 circulated predominantly for 10 years (Figure 1, panel B), alternating with DENV-1 through 2 periods of resurgence during the 1990s and cocirculation of DENV-4 (Figure 1, panel B). DENV-2 declined markedly after the 1998 epidemic and the dissemination of DENV-3 concomitant to the disappearance of DENV-1 and -4. However, DENV-2 continued to cause a low number of cases during 1999–2003 and reemerged in 2004–2007 (Figure 1, panel B). Samples from every year of the 22-year study period (Figure 1, panel C) comprised our analysis.

Figure 2

Thumbnail of Evolution of dengue virus (DENV) serotype 2, Puerto Rico. Maximum likelihood phylogeny of the 140 Puerto Rico and 20 international isolates of DENV-2 (see number of isolates by year below). Names of clades (I, II, and III) and subclades (IA, IB) are shown at the base of their respective branches on the phylogeny tree. Clade II (dark blue) circulated during 1986–1996 and clade I (light blue) during 1994–2007. Subclade IA and clade III represent foreign, transient reintroductions thro

Figure 2. Evolution of dengue virus (DENV) serotype 2, Puerto Rico. Maximum likelihood phylogeny of the 140 Puerto Rico and 20 international isolates of DENV-2 (see number of isolates by year below). Names...

The Bayesian Skyline analysis (Figure 1, panel D) of the autochthonous viral sequences (Figure 2; clades IB and II Figure A1) showed a gradual increase in the genetic diversity of DENV-2 during 1987–1991 that corresponds to a period of high transmission and dominance (Figure 1, panel B). This increase was followed by 9 years of high genetic diversity that coincided with a period of DENV-1 and DENV-4 cocirculation. The genetic diversity of DENV-2 declined sharply during 1999–2003, coinciding with a period of minimal DENV-2 transmission. Genetic diversity rebounded in 2005 to roughly pre-1999 levels as the virus reemerged.

The densely populated island of Puerto Rico (3,808,610 population; 3,508 square miles) is divided into 78 municipalities grouped in 8 regions. The 140 DENV-2 genomes from 37 municipalities represented all 8 regions and ranged from 2–20 isolates per year (Figure 1, panel C; Figure 2). We included 20 other sequences from Caribbean countries. The number of Puerto Rico sequences is proportional to the epidemic level or the relative proportion of DENV-2 identifications in the municipalities with highest DENV-2 reporting per year. The phylogeny of the 160 DENV-2 genomes showed 2 major clades (I and II) and a smaller clade (III) (Figure 2). Clade I contains 115 sequences and can be further subdivided in 2 subclades. Subclade IA (1998–2007) contains 13 Puerto Rico and 12 Caribbean sequences, including 1 from St. Thomas (SH 90 FJ898450) identified as the closest ancestor. Subclade IB (1994–2007) contains 90 sequences mostly of local origin, but the presence of 6 foreign and 1 local basal sequences confirms its foreign origin. Clade II (1986–1994) contains 39 local isolates. Basal to clades I and II is a St. John 1987 sequence (SJ 87 GQ868603), which suggests a possible origin. Clade III is formed by 4 local isolates during1987–1991. These genetically distinct isolates do not fit in clade I or II, but a separate analysis with publically available envelope gene sequences pointed to possible Caribbean origin (K.L. McElroy et al., unpub. data).

Four events merit recognition (Figure 2). First, a mixture of foreign and local strains at the base of subclades IA and IB provides evidence of multiple introductions. Eight Puerto Rico viruses associated with these foreign strains date from 1994 through 1999. These years also are associated with a distinct subgroup basal to subclade IB concomitant with the extinction of clade II in 1997. Second, subclade IB evolved mainly after the introduction of DENV-3 in 1998. Third, a period of limited circulation of DENV-2 reflected in low levels of genetic diversity (1999–2003) coincided with the expansion of DENV-3 and decline of DENV-1 and -4. Fourth, there was a resurgence of DENV-2 during 2004–2007.

Forty-nine amino acid differences mapped to the phylogeny were detected across the major internal branches of the tree. Twenty of these comprise major differences between clades I and II and between subclades IA and IB, as well as substitutions that arose during the continuous evolution of subclade IB (Figure 2). Only 1 aa substitution distinguished isolates in clades I/II from III: a hydrophilic glutamine to a hydrophobic leucine at position 131 in the E protein. Excluding PR79_1995_EU569708 as a possible foreign introduction, 18 aa differences distinguish isolates across clade I, 12 of which separate subclade IB from clade II and potentially could have been involved in the 1994–1997 lineage turnover (Figure 2). The remaining differences between isolates in subclades IB and II were present in nonstructural (NS) genes and are preponderantly conservative mutations, with the exception of position 31 in NS3, which was nonconservative. Among the additional changes, the only nonconservative mutation was a hydrophobic alanine to hydrophilic threonine at position 137 in NS4B that originated with PR40_1999 EU482730, and most changes were found in the NS genes.

Using Bayesian MCMC and dN/dS analyses, we estimated the mean substitution rates for the full genomes at 9 × 10–4 to 1.1 × 10–3 for all clades, consistent with previously published rates (20,21). The low dN/dS ratios (0.07–0.08) provide evidence of a low percentage of substitutions that have been fixed along independent lineages, possibly indicating purifying, negative selection.

Figure 3

Thumbnail of Geographic clustering of Puerto Rico dengue virus lineages. A) Maximum-likelihood phylogeny of clade II. All isolates indicate year of case presentation and GenBank accession numbers. B) Maximum-likelihood phylogeny of subclade IB shows isolates by year and GenBank accession numbers. Six regions had &gt;5 isolates (San Juan, Caguas, Ponce, Mayaguez, Aguadilla, and Arecibo). C) Eight regions of Puerto Rico with colors corresponding to isolates in panel A and year for the 3 regions wi

Figure 3. Geographic clustering of Puerto Rico dengue virus lineages. A) Maximum-likelihood phylogeny of clade II. All isolates indicate year of case presentation and GenBank accession numbers. B) Maximum-likelihood phylogeny of subclade IB...

BaTS analysis shows that lineages often correlated with the corresponding region of origin of the isolates. Seven of the 8 regions had >4 isolates in subclade IB or clade II. This association was significant for 6 regions (p<0.05) (Table). The most significant geographic correlation of lineages were found in the San Juan (1986–1990 and 1994–1996), Ponce (1987–1989), and Mayaguez (1989 and 1993) (Figure 3, panel A). In addition, isolates clustered geographically for San Juan (1997–1999 and 2001–2006), Caguas (1998–2001, 2004, and 2005), Ponce (1995–1997 and 2005), Mayaguez (1996–1998 and 2006), Aguadilla (1996–1998), and Arecibo (1994–1995, 2004, and 2006) (Figure 3, panel B ). Considering the DENV-2 historical data, we recognize that high-reporting municipalities usually are located in regions where we identified significant phylogenetic clustering (Figure A1). For example, in 1987, most DENV-2 cases originated from the Ponce and San Juan regions, where we identified lineages of clade I. For1994–1996, DENV-2 cases in San Juan, Ponce, Mayaguez, and Arecibo regions may reflect the coexistance of subclades IB and clade II.

We investigated other possible associations with the DENV-2 phylogeny, including age and DF/DHF status, but found none. Most DENV-2 infections were secondary (84.6% and 77% of DENV-2 infections in the CDC collection and this study, respectively). However, we found no relationship between phylogeny and incidence of primary or secondary infection in patients.

Figure 4

Thumbnail of Epidemiology of dengue virus (DENV) serotype 2 in Puerto Rico, 1997–2006. A) Municipalities with persistent DENV-2 transmission (Caguas, Juncos, Las Piedras, Carolina) versus those with discontinuous transmission (Morovis, Toa Alta, Toa Baja, Cataño, Guaynabo, Cidra, San Lorenzo, Canóvanas, Humacao, Naguabo, Ceiba, Fajardo), 1998–2002. Inset shows satellite view; red dot indicates national capital (San Juan), and yellow box indicates region where DENV-2 took refuge during 2000–2002.

Figure 4. Epidemiology of dengue virus (DENV) serotype 2 in Puerto Rico, 1997–2006. A) Municipalities with persistent DENV-2 transmission (Caguas, Juncos, Las Piedras, Carolina) versus those with discontinuous transmission (Morovis, Toa Alta, Toa...

Figure 5

Thumbnail of Incidence of dengue virus (DENV) serotypes 2 and 3 in Puerto Rico, 1996–2005. Solid blue line, incidence of DENV-2 within the refuge region; dashed blue line, incidence of DENV-2 in the rest of the island outside the refuge reason; solid black line, incidence of DENV-3 within the DENV-2 refuge region; dashed black line) incidence of DENV-3 in the rest of the island outside the refuge region. Incidence was calculated as number of confirmed, positive cases of each serotype per thousan

Figure 5. Incidence of dengue virus (DENV) serotypes 2 and 3 in Puerto Rico, 1996–2005. Solid blue line, incidence of DENV-2 within the refuge region; dashed blue line, incidence of DENV-2 in the...

The year 1999 began a period of low circulation and low genetic diversity of the Caguas lineage of subclade IB (Figure 1, panel D; Figure 2; Figure 3, panel B) that lasted until 2003. During these 4 years, most DENV-2 cases originated from only 4 municipalities in eastern Puerto Rico (Figure 4, panel A); <20 additional DENV-2 cases were reported during that period in 12 other neighboring municipalities (Figure 4, panel A). Because phylogenetic lineages are geographically and temporally clustered, (Figure 2), we illustrated these associations on the map of Puerto Rico (Figure 4). This map shows that DENV-2 descendants from western Puerto Rico emerged in San Juan in 1997–1998 (Figure 4, panel B, top), then appeared and persisted within the refuge in 1999–2002 (Figure 4, panel C, middle) to then disseminate across the island in 2003–2005 (Figure 4, panel D). In the 4 municipalities with uninterrupted DENV-2 transmission, DENV-2 incidence increased 2 years after the islandwide increase (Figure 5). DENV-3 incidence within this DENV-2 refuge was minimal during the period of high DENV-2 incidence but peaked 2 years later concomitant with an increase across the rest of the island


Puerto Rico is a model for fine-scale studies on DENV evolution in the Americas. The long-term persistence of DENV-2 and its ability to reemerge after transient periods of low circulation is a remarkable aspect of the epidemiology of dengue in the region. The fact that 13% of DENV-2 isolates represent importations or close descendants from importations brings new insights to our understanding of DENV long-term circulation. Foreign viruses were identified in 8 years (1987, 1989, 1991, 1995, 1998, 1999, 2005, and 2007), of which only 1991 and 1998 had been previously sampled (14). Ten of the 18 introductions occurred during periods of high DENV-2 predominance: 1987–1991, 1995, and 2005–2007 (Figure 1, panel B; Figure 2). The other 8 introductions originated from the 1998 epidemic or shortly thereafter (1999). Therefore, DENV-2 seems to be introduced mainly during periods of favorable preponderance, not necessarily epidemic transmission of this serotype. Subclade IA viruses never established themselves, regardless of year of isolation or origin. These assessments showed a previously unknown feature of DENV-2 persistence: the endemic strain is recalcitrant to influences from frequent foreign introductions.

The relative inability of “foreign” DENV-2 to persist in the presence of the dominant subclade IB viruses is not well understood. The Puerto Rico strain might be highly adapted and thus have a fitness advantage, the frequently introduced strains might be simply underrepresented, or introduced strains may have disappeared through genetic drift. Isolate PR76_1995_EU569708, which lies basal to this subclade in the phylogeny (Figure 2), is more closely related to South American DENV-2 viruses than to other Puerto Rico viruses, and this lineage does not appear to have progressed, supporting the foreign origin of subclade IB. Our findings then show that subclade IB resulted from an introduced strain, as previously suggested by Bennett et al. (14), and successfully penetrated during a period of proportionally high incidence of foreign introductions. Interestingly, this clade replacement was completed in 1997, less than a year before the finding of DENV-3 and the concomitant decline of DENV-1, -2, and -4. The early portion of subclade IB is seen as a period of short-lived lineages ending in 1997, therefore, the rise and expansion of this subclade mainly occurs in coexistence with DENV-3, a different epidemiologic scenario from that of the now extinct clade II a decade earlier.

The dominance of conservative amino acid changes that segregated the viruses by clade hinders the assessment of phenotypic changes. Compensatory mutations might have conferred replicative advantages that could have influenced the displacement of clade II or the persistence of subclade IB in Puerto Rico; however this hypothesis has not been tested. Positive selection was not identified, contrasting with previous analyses (14,2224). Others have not detected positive selection and attribute lineage extinctions or clade replacements to stochastic events rather than natural selection (25). More analysis to detect site-specific selection is needed to corroborate whether positive selection is not at play in these populations of viruses.

The period 1999–2003 represents historically low rates of DENV-2 circulation (Figures 1, 2, 4), and the epidemiologic and phylogenetic aspects of this transient retrieval had not been studied previously. We show that the genetic variability of DENV-2 decreased during these 4 years when the virus was transmitted in only a subset of municipalities. DENV-2 represented 29% of the cases in this area but only 5% island-wide. The reason this region became a refuge of DENV-2 for 4 years remains unclear, but the low incidence of DENV-2 in prior years compared with the rest of the island suggests susceptibility for infection in this population (Figure 5). Studies in Thailand showed serotype displacement affecting population diversity and lineage turnover (26). Short-term serotype cross-protection has been suggested to contribute to serotype displacements (2729), implying that as DENV-3 infected a large susceptible population, cross-protective antibodies momentarily impeded transmission of other serotypes and dissemination of DENV-2 outside the eastern refuge. Our study confirms the utility of systematic sampling and genome sequencing in large-scale surveillance systems as ways to understand the dynamics of dengue transmission and endemicity.

Dr McElroy received her PhD from the University of Texas Medical Branch, Galveston, TX, USA. At the time this study was conducted, she was a postdoctoral research fellow at the Dengue Branch, Division of Vector-Borne Diseases, National Center for Emerging and Zoonotic Infectious Diseases, CDC. Her research interests include the molecular entomology of flaviviruses.



We thank Vance Vorndam, Mark Verduin, Candimar Colón, and Edgardo Vergne for providing laboratory support; Luis Santiago for statistical analysis; and Eddie Holmes for scientific consultation. International isolates were provided by Caribbean Epidemiology Centre, Trinidad and Tobago; Instituto Nacional de Diagnostico y Referencia Epidemiologicos, Mexico; and Laboratorio Regional de Diagnóstico e Investigación del Dengue y Otras Enfermedades Virales, Venezuela.

This project was funded in part by the National Institutes of Health, contract HHSN266200400001C (B.W.B.).



  1. Gubler  DJ. Dengue/dengue haemorrhagic fever: history and current status. Novartis Found Symp. 2006;277:3–16; discussion 1622, 71–3, 251–3.
  2. Dietz  V, Gubler  DJ, Ortiz  S, Kuno  G, Casta-Velez  A, Sather  GE, The 1986 dengue and dengue hemorrhagic fever epidemic in Puerto Rico: epidemiologic and clinical observations. P R Health Sci J. 1996;15:20110.PubMedGoogle Scholar
  3. Rigau-Pérez  JG, Vorndam  AV, Clark  GG. The dengue and dengue hemorrhagic fever epidemic in Puerto Rico, 1994–1995. Am J Trop Med Hyg. 2001;64:6774.PubMedGoogle Scholar
  4. Rigau-Pérez  JG, Ayala-Lopez  A, Garcia-Rivera  EJ, Hudson  SM, Vorndam  V, Reiter  P, The reappearance of dengue-3 and a subsequent dengue-4 and dengue-1 epidemic in Puerto Rico in 1998. Am J Trop Med Hyg. 2002;67:35562.PubMedGoogle Scholar
  5. Lewis  JA, Chang  GJ, Lanciotti  RS, Kinney  RM, Mayer  LW, Trent  DW. Phylogenetic relationships of dengue-2 viruses. Virology. 1993;197:21624. DOIPubMedGoogle Scholar
  6. Vorndam  V, Kuno  G, Rosado  N. A PCR-restriction enzyme technique for determining dengue virus subgroups within serotypes. J Virol Methods. 1994;48:23744. DOIPubMedGoogle Scholar
  7. Foster  JE, Bennett  SN, Vaughan  H, Vorndam  V, McMillan  WO, Carrington  CV. Molecular evolution and phylogeny of dengue type 4 virus in the Caribbean. Virology. 2003;306:12634. DOIPubMedGoogle Scholar
  8. Leitmeyer  KC, Vaughn  DW, Watts  DM, Salas  R, Villalobos  I, de Chacon, et al. Dengue virus structural differences that correlate with pathogenesis. J Virol. 1999;73:473847.PubMedGoogle Scholar
  9. Rico-Hesse  R, Harrison  LM, Salas  RA, Tovar  D, Nisalak  A, Ramos  C, Origins of dengue type 2 viruses associated with increased pathogenicity in the Americas. Virology. 1997;230:24451. DOIPubMedGoogle Scholar
  10. Guzman  MG, Deubel  V, Pelegrino  JL, Rosario  D, Marrero  M, Sariol  C, Partial nucleotide and amino acid sequences of the envelope and the envelope/nonstructural protein-1 gene junction of four dengue-2 virus strains isolated during the 1981 Cuban epidemic. Am J Trop Med Hyg. 1995;52:2416.PubMedGoogle Scholar
  11. Gubler  DJ. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol. 2002;10:1003. DOIPubMedGoogle Scholar
  12. Rico-Hesse  R. Dengue virus evolution and virulence models. Clin Infect Dis. 2007;44:14626. DOIPubMedGoogle Scholar
  13. Chaturvedi  UC. The curse of dengue. Indian J Med Res. 2006;124:46770.PubMedGoogle Scholar
  14. Bennett  SN, Holmes  EC, Chirivella  M, Rodriguez  DM, Beltran  M, Vorndam  V, Molecular evolution of dengue 2 virus in Puerto Rico: positive selection in the viral envelope accompanies clade reintroduction. J Gen Virol. 2006;87:88593. DOIPubMedGoogle Scholar
  15. Miagostovich  MP, Nogueira  RM, dos Santos  FB, Schatzmayr  HG, Araujo  ES, Vorndam  V. Evaluation of an IgG enzyme-linked immunosorbent assay for dengue diagnosis. J Clin Virol. 1999;14:1839. DOIPubMedGoogle Scholar
  16. Gubler  DJ, Kuno  G, Sather  GE, Velez  M, Oliver  A. Mosquito cell cultures and specific monoclonal antibodies in surveillance for dengue viruses. Am J Trop Med Hyg. 1984;33:15865.PubMedGoogle Scholar
  17. Maddison  WP, Maddison  DR. Interactive analysis of phylogeny and character evolution using the computer program MacClade. Folia Primatol (Basel). 1989;53:190202. DOIPubMedGoogle Scholar
  18. Rigau-Perez  JG, Ayuso-Lamadrid  A, Wolff  DR, Reiter  P, Kuno  G. Dengue severity throughout seasonal changes in incidence in Puerto Rico, 1989–1992. The Puerto Rico Association of Epidemiologists. Am J Trop Med Hyg. 1994;51:40815.PubMedGoogle Scholar
  19. Tomashek  KM, Rivera  A, Munoz-Jordan  JL, Hunsperger  E, Santiago  L, Padro  O, Description of a large island-wide outbreak of dengue in Puerto Rico, 2007. Am J Trop Med Hyg. 2009;81:46774.PubMedGoogle Scholar
  20. Carrington  CV, Foster  JE, Pybus  OG, Bennett  SN, Holmes  EC. Invasion and maintenance of dengue virus type 2 and type 4 in the Americas. J Virol. 2005;79:146807. DOIPubMedGoogle Scholar
  21. Twiddy  SS, Holmes  EC, Rambaut  A. Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol. 2003;20:1229. DOIPubMedGoogle Scholar
  22. Kumar  SR, Patil  JA, Cecilia  D, Cherian  SS, Barde  PV, Walimbe  AM, Evolution, dispersal and replacement of American genotype dengue type 2 viruses in India (1956–2005). Selection pressure and molecular clock analyses. J Gen Virol. 2010;91:70720. DOIPubMedGoogle Scholar
  23. Twiddy  SS, Woelk  CH, Holmes  EC. Phylogenetic evidence for adaptive evolution of dengue viruses in nature. J Gen Virol. 2002;83:167989.PubMedGoogle Scholar
  24. Bennett  SN, Holmes  EC, Chirivella  M, Rodriguez  DM, Beltran  M, Vorndam  V, Selection-driven evolution of emergent dengue virus. Mol Biol Evol. 2003;20:16508. DOIPubMedGoogle Scholar
  25. Myat Thu  H, Lowry  K, Jiang  L, Hlaing  T, Holmes  EC, Aaskov  J. Lineage extinction and replacement in dengue type 1 virus populations are due to stochastic events rather than to natural selection. Virology. 2005;336:16372. DOIPubMedGoogle Scholar
  26. Zhang  C, Mammen  MP Jr, Chinnawirotpisan  P, Klungthong  C, Rodpradit  P, Monkongdee  P, Clade replacements in dengue virus serotypes 1 and 3 are associated with changing serotype prevalence. J Virol. 2005;79:1512330. DOIPubMedGoogle Scholar
  27. Adams  B, Holmes  EC, Zhang  C, Mammen  MP Jr, Nimmannitya  S, Kalayanarooj  S, Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok. Proc Natl Acad Sci U S A. 2006;103:142349. DOIPubMedGoogle Scholar
  28. Forshey  BM, Morrison  AC, Cruz  C, Rocha  C, Vilcarromero  S, Guevara  C, Dengue virus serotype 4, northeastern Peru, 2008. Emerg Infect Dis. 2009;15:18158.PubMedGoogle Scholar
  29. Vu  TT, Holmes  EC, Duong  V, Nguyen  TQ, Tran  TH, Quail  M, Emergence of the Asian 1 genotype of dengue virus serotype 2 in Viet Nam: in vivo fitness advantage and lineage replacement in South-East Asia. PLoS Negl Trop Dis. 2010;4:e757. DOIPubMedGoogle Scholar




Cite This Article

DOI: 10.3201/eid1701.100961

1These authors contributed equally to this article.

Table of Contents – Volume 17, Number 1—January 2011

EID Search Options
presentation_01 Advanced Article Search – Search articles by author and/or keyword.
presentation_01 Articles by Country Search – Search articles by the topic country.
presentation_01 Article Type Search – Search articles by article type and issue.



Please use the form below to submit correspondence to the authors or contact them at the following address:

Jorge L. Muñoz-Jordán, Centers for Disease Control and Prevention, 1324 Calle Cañada, San Juan, PR 00920, USA

Send To

10000 character(s) remaining.


Page created: July 08, 2011
Page updated: July 08, 2011
Page reviewed: July 08, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.